NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
NovaBridge Biosciences NBP
9 fiscal years on record · CNY · FY2025 reported · SEC filings only
$-46.3M
CNY -20.6M
Growth
—
Revenue, FY2025 · full 9-year series below
Revenue CNY B
Net income CNY B
FY2021 · Revenue 0.1 · Net income -2.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2023 · Operating -11395.1% · Net -32868.5%
ROE
FY2025 · ROE -21.4%
Each CNY of equity lost 21 cents this year.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · CNY
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue CNY B | · | · | · | · | 0.1 | 1.5 | 0.0 | 0.1 | 0.0 |
| Operating income CNY B | · | · | · | · | −2.3 | 0.5 | −1.5 | −0.4 | −0.3 |
| EBITDA CNY B | −0.1 | −0.1 | −0.1 | −0.1 | −2.3 | 0.5 | −1.4 | −0.4 | −0.3 |
| Income tax CNY B | · | · | · | · | −0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income CNY B | · | · | · | · | −2.3 | 0.5 | −1.5 | −0.4 | −0.3 |
| Free cash flow CNY B | −0.0 | −0.1 | −0.1 | −0.1 | −1.0 | 0.4 | −0.9 | −0.3 | −0.3 |
| EPS, diluted CNY | · | · | · | · | · | · | · | · | −51.93 |
| Dividend / sh CNY | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | −21.4 | −10.0 | −62.9 | −65.5 | · | 26.2 | · | · | · |
| Shares out B | 0.27 | 0.19 | 0.19 | 0.19 | 0.18 | 0.16 | 0.01 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 5 failures in 27 reconciliationsAUDITED
Reconciled in 4 of 19 fiscal years. 64 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente5 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2017